{
  "_metadata": {
    "version": "2.0",
    "extracted_from": "ARWR Investment Thesis, Company Presentations",
    "extraction_date": "2026-02-05",
    "analyst_reviewed": true
  },
  "asset": {
    "name": "Zodasiran",
    "alternate_names": ["ARO-ANG3"],
    "company": "Arrowhead Pharmaceuticals",
    "ticker": "ARWR",
    "stage": "Phase 2/3",
    "modality": "RNAi (siRNA)",
    "ownership": "Partnered with Amgen",
    "one_liner": "Dual LDL-C and TG reduction via ANGPTL3 silencing with quarterly dosing"
  },
  "target": {
    "name": "ANGPTL3",
    "full_name": "Angiopoietin-like 3",
    "class": "Lipid metabolism regulator",
    "pathway": "Lipid metabolism - inhibits LPL and endothelial lipase",
    "biology": {
      "simple_explanation": "ANGPTL3 is a liver-secreted protein that inhibits both lipoprotein lipase (LPL) and endothelial lipase. By silencing ANGPTL3, zodasiran unleashes both enzymes, lowering BOTH triglycerides and LDL-cholesterol.",
      "pathway_detail": "ANGPTL3 inhibits LPL (clearing TG) and endothelial lipase (clearing HDL phospholipids, affecting LDL metabolism). Loss of ANGPTL3 function leads to reduced LDL-C, TG, and paradoxically increased clearance of atherogenic lipoproteins.",
      "downstream_effects": [
        "65% LDL-C reduction",
        "70% TG reduction",
        "Reduced atherogenic lipoprotein particles"
      ]
    },
    "why_good_target": {
      "clinical_validation": "Evinacumab (ANGPTL3 antibody) approved for HoFH",
      "genetic_validation": {
        "loss_of_function": "ANGPTL3 LoF mutations associated with lower LDL, lower TGs, reduced CV events (familial combined hypolipidemia)"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    }
  },
  "mechanism": {
    "type": "RNAi (siRNA) via TRiM platform",
    "delivery": "GalNAc-conjugated for hepatocyte targeting",
    "how_it_works": "Zodasiran silences ANGPTL3 mRNA in hepatocytes, reducing circulating ANGPTL3 protein. This releases inhibition of LPL and endothelial lipase, enabling accelerated clearance of TG-rich and LDL particles.",
    "potency": {
      "ldl_c_reduction": "65%",
      "tg_reduction": "70%"
    },
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "indications": {
    "lead": {
      "name": "Homozygous Familial Hypercholesterolemia (HoFH)",
      "patient_population": "~3,000 US patients",
      "status": "Phase 3 recruiting",
      "rationale": "Severe genetic dyslipidemia with inadequate LDL control despite max therapy"
    },
    "expansion": [
      {
        "name": "Mixed Dyslipidemia",
        "patient_population": "Large",
        "status": "Phase 2",
        "rationale": "Dual LDL and TG reduction fills unmet need"
      },
      {
        "name": "ASCVD Risk Reduction",
        "patient_population": "Very large",
        "status": "Early evaluation",
        "rationale": "CV outcomes potential"
      }
    ],
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "clinical_data": {
    "arches2_phase2": {
      "trial_name": "ARCHES-2",
      "nct_id": "NCT04832971",
      "design": {
        "type": "Randomized, placebo-controlled",
        "population": "Patients with mixed dyslipidemia"
      },
      "results": {
        "ldl_c_reduction": "-55%",
        "interpretation": "Validates dual lipid-lowering mechanism"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    },
    "ongoing_trials": [
      {
        "trial_name": "Gateway",
        "nct_id": "NCT05217667",
        "phase": "Phase 2",
        "indication": "Mixed dyslipidemia",
        "status": "Active, not recruiting"
      },
      {
        "trial_name": "Zodasiran Phase 3 HoFH",
        "nct_id": "NCT07037771",
        "phase": "Phase 3",
        "indication": "Homozygous Familial Hypercholesterolemia",
        "status": "Recruiting",
        "data_expected": "2026-2027"
      }
    ]
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "ANGPTL3 is genetically validated",
        "evidence": "LOF mutations show low LDL, low TGs, reduced CV events",
        "confidence": "High"
      },
      {
        "point": "Dual LDL-C (65%) and TG (70%) reduction with quarterly dosing",
        "evidence": "ARCHES-2 Phase 2 data",
        "confidence": "High"
      },
      {
        "point": "Superior to evinacumab",
        "evidence": "65% vs 47% LDL-C reduction, quarterly SC vs monthly IV",
        "confidence": "Medium - different patient populations"
      }
    ],
    "bear_case": [
      {
        "point": "Crowded lipid market",
        "evidence": "Statins and PCSK9 inhibitors already available",
        "counter_argument": "Different mechanism, additive benefit for high-risk patients"
      },
      {
        "point": "Evinacumab already approved for HoFH",
        "evidence": "Regeneron has first-mover advantage",
        "counter_argument": "Zodasiran more efficacious, more convenient dosing"
      },
      {
        "point": "Quarterly injection vs daily statin",
        "evidence": "Convenience advantage over biologics, not oral drugs",
        "counter_argument": "For severe patients already on injections, quarterly is improvement"
      }
    ],
    "key_debates": [
      {
        "question": "Can zodasiran demonstrate CV outcomes benefit?",
        "bull_view": "Genetic validation strong; dual lipid lowering may be superior",
        "bear_view": "CV outcomes trials expensive and long; may not be conducted",
        "what_resolves_it": "Phase 3 HoFH data, potential outcomes study"
      }
    ]
  },
  "competitive_landscape": [
    {
      "competitor": "Evinacumab (Evkeeza)",
      "company": "Regeneron",
      "mechanism": "ANGPTL3 antibody",
      "stage": "Approved (HoFH)",
      "efficacy": "47% LDL-C reduction",
      "differentiation": "Zodasiran shows higher efficacy (65% vs 47%), quarterly SC vs monthly IV"
    }
  ],
  "catalysts": [
    {
      "event": "Phase 3 HoFH data",
      "timing": "2026-2027",
      "importance": "Critical",
      "what_to_watch": "LDL-C reduction vs placebo in HoFH"
    }
  ],
  "sources": [
    {
      "id": "arwr_thesis_2026",
      "title": "ARWR Investment Thesis",
      "type": "Internal Analysis",
      "date": "2026-02-02"
    },
    {
      "id": "clinicaltrials",
      "title": "ClinicalTrials.gov",
      "type": "Clinical Trial Registry",
      "url": "https://clinicaltrials.gov/api/v2/studies"
    }
  ]
}
